Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06235086
Other study ID # SYSA1803-009
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date March 2024
Est. completion date November 2026

Study information

Verified date January 2024
Source CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Contact Clinical Trials Information Group officer
Phone 86-0311-69085587
Email ctr-contact@cspc.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, open-label, dulaglutide-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, and immunogenicity of different doses of TG103 injection in combination with metformin in subjects with type 2 diabetes with poor glycemic control treated with metformin monotherapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 618
Est. completion date November 2026
Est. primary completion date March 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Subjects have diagnosed with type 2 diabetes according to the Guidelines for prevention and treatment of type 2 diabetes in China (2020 Edition), T2DM was diagnosed at least 8 weeks before screening; - Aged 18 to 75 years (inclusive), no gender limitation; - Body Mass Index (BMI): 18.5=BMI=40; - Received stable dose of metformin hydrochloride monotherapy for =8 weeks before screening and metformin dose =1500 mg/ day or maximum tolerated dose (<1500 mg/ day but =1000 mg/ day); - HbA1c must meet the following criteria: - Screening: 7.5% = HbA1c = 11.0% (Local laboratory) - Baseline: 7.0% = HbA1c = 10.5% (Central laboratory) - Subjects of childbearing potential must use reliable methods of contraception throughout the study period and at least 3 months after the last dose to avoid pregnancy in female subjects or pregnancy in the male subject's partner; - Willing and able to accurately use home glucose meter for self-glucose monitoring; - Be able to understand and follow the trial procedure, voluntarily participate in the trial and sign the informed consent form. Exclusion Criteria: - Type 1 diabetes; - Body weight change more than 5% within 1 month prior to screening; - Received any of the following medications: 1. Prior discontinuation of DPP-4 inhibitors or GLP-1 receptor agonists for efficacy, tolerability, and safety reasons; 2. Systemic glucocorticoid and growth hormone have been used within 8 weeks before screening; - History of =2 episodes of grade 3 hypoglycemia within 6 months prior to screening, or grade 3 hypoglycemia between screening to randomization; - Acute complications of diabetes, such as diabetic ketoacidosis and hyperglycemic hyperosmolar status, occurred =1 time within 6 months prior to screening; - Severe chronic complications of diabetes (e.g., proliferative diabetic retinopathy, severe diabetic neuropathy, diabetic foot, etc.) within 6 months prior to screening - History of acute or chronic pancreatitis prior to screening; - Subjects with clinically significant gastric emptying abnormalities (e.g., gastric outlet obstruction), severe chronic gastrointestinal diseases (e.g., gastroparesis, inflammatory bowel disease, or intestinal obstruction) within 6 months prior to screening, or who have undergone gastrointestinal surgery that affects gastric emptying; - Any of the following cardiovascular events within 6 months prior to screening: decompensated cardiac insufficiency (NYHA class III or IV); history of unstable angina pectoris, myocardial infarction, coronary artery bypass grafting, or coronary stent implantation; or long QT syndrome or prolonged QTcF interval (QTcF: male >450 ms, female >470 ms) on 12-lead ECG; severe arrhythmias that are evaluated by the investigator to be inappropriate for participation in this clinical trial; - Hemorrhagic stroke or acute ischemic stroke disease occurred within 6 months prior to screening, or prior to randomization; - History of psychiatric diseases (such as depression, anxiety, etc.) during screening; or symptomatic gallbladder disease; or history of other diseases that may endanger the safety of the subject and that the investigator deems inappropriate for enrollment; - Any type of malignant tumor treated or untreated within 5 years prior to screening (except for clinically cured basal cell carcinoma or carcinoma in situ); - Severe or acute infection within 4 weeks prior to screening, or refractory urinary tract or genital infection within 6 months prior to screening; - Having a significant blood system disease (e.g., aplastic anemia, myelodysplastic syndrome) or any disease causing hemolysis or red blood cell instability (e.g., malaria) at screening; - Subjects with thyroid dysfunction that cannot be controlled by a stable drug dose at screening, or with clinically significant abnormalities in thyroid function examination results requiring drug treatment at screening; - Personal or family history of medullary thyroid cancer (MTC) or type 2 multiple endocrine tumor syndrome at screening; - Any of the indicators meet the following criteria: - i. Systolic blood pressure = 160mmHg or diastolic blood pressure = 100mmHg at screening or before randomization; - ii. Laboratory tests show any of the following abnormalities: 1. FPG=13.9 mmol/L; 2. ALT or AST=2.5×ULN; 3. Total bilirubin (TBiL) =2.0×ULN; 4. Triglyceride >5.7 mmol/L; 5. eGFR<45 mL/(min*1.73 m^2); 6. Serum amylase and/or lipase =3×ULN; 7. Hemoglobin <100 g/L; 8. Calcitonin=50 ng/L(pg/mL); - iii. Serological examination: 1. Human immunodeficiency virus antibody or treponema pallidum antibody is positive; 2. Hepatitis C antibody is positive, and HCV RNA was higher than the lower limit of the detection reference range; 3. Hepatitis B surface antigen is positive, and the quantitative detection result of HBV DNA was higher than the lower limit of the detection reference range; - Known allergy to the test drug, Dulaglutide, Empagliflozin, or related excipients; - Subjects who have lost more than 400 mL blood due to blood donation or other reasons within 3 months prior to screening; - Average alcohol intake more than 21 units of alcohol (male)/14 units of alcohol (female) per week within the 3 months prior to screening (1 unit ˜360 mL beer, or 45 mL spirits with 40% alcohol content, or 150 mL wine); - Subject participated in any drug or medical device clinical study within 3 months prior to screening (except for screening failure); - Pregnant or lactating female; - Not suitable for this study in the investigator's opinion.

Study Design


Intervention

Drug:
TG103
TG103 injection, 7.5mg, 15 mg, SC, once a week
Dulaglutide
Dulaglutide, SC, once a week

Locations

Country Name City State
China Peking University People's Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in glycosylated hemoglobin (HbA1c) from baseline at 28 weeks of treatment Baseline through Week28
Secondary Changes in HbA1c from baseline at 52 weeks of treatment Baseline through Week52
Secondary The percentage of HbA1c=6.5% and the percentage of HbA1c=7% at week 28 and 52 Week28 and 52
Secondary Change in fasting plasma glucose (FPG) from baseline at week 28 and 52 Baseline through Week28 and 52
Secondary Change in weight from baseline at week 28 and 52 Baseline through Week28 and 52
Secondary Change in 2h-postprandial plasma glucose (2h-PPG) from baseline at week 28 and 52 Baseline through Week28 and 52
Secondary Mean 7 point blood glucose curve from baseline at week 28 and 52. Change in mean postprandial blood glucose increment from baseline at week 28 and 52. Baseline through Week28 and 52
Secondary Change in blood lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) from baseline at week 28 and 52. Baseline through Week28 and 52
Secondary Proportion of subjects receiving remedial therapy at week 28 and 52 Week28 and 52
Secondary Incidence of adverse events Week-2 through 52
Secondary Blood concentrations of TG103 Week 0, 4, 8,16, 28, 36, 44, 52 and 55
Secondary The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (NAb). Week 0, 4, 8,16, 28, 36, 44, 52 and 55
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Recruiting NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02226003 - Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017) Phase 3